Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes-Reference-Cited by-同舟云学术

Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes

Published:2022-03-08 Issue:6 Volume:24 Page:1061-1071
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obesity Metabolism

Author:

Kahl Sabine¹²³^ORCID,Ofstad Anne Pernille⁴^ORCID,Zinman Bernard⁵^ORCID,Wanner Christoph⁶^ORCID,Schüler Elke⁷^ORCID,Sattar Naveed⁸^ORCID,Inzucchi Silvio E.⁹^ORCID,Roden Michael¹²³^ORCID

Affiliation:

1. Institute for Clinical Diabetology, German Diabetes Center Leibniz Institute for Diabetes Research at Heinrich‐Heine University Düsseldorf Germany

2. Department of Endocrinology and Diabetology, Medical Faculty and University Hospital Düsseldorf Heinrich‐Heine‐University Düsseldorf Düsseldorf Germany

3. German Center for Diabetes Research München‐Neuherberg Germany

4. Medical Department Boehringer Ingelheim Norway KS Asker Norway

5. Lunenfeld‐Tanenbaum Research Institute, Mount Sinai Hospital University of Toronto Toronto Ontario Canada

6. Würzburg University Clinic Würzburg Germany

7. mainanalytics GmbH Sulzbach Germany

8. Institute of Cardiovascular and Medical Sciences University of Glasgow, BHF Glasgow Cardiovascular Research Centre (GCRC) Glasgow UK

9. Yale University School of Medicine New Haven Connecticut USA

Funder

Boehringer Ingelheim

Publisher

Wiley

Subject